OROS methylphenidate in the treatment of adults with ADHD: A 6-month, open-label, follow-up study

Background: This open-label trial followed a previously reported randomized, placebo-controlled trial of osmotic release oral system (OROS) methylphenidate (MPH) for the treatment of personality disorder (PD). Important findings from the double-blind phase are reexamined for long-term significance.

Purchase this article:


For unlimited access to all issues and articles: